Human papillomavirus E2 protein is a transcription factor of viral gene expression and DNA replication. Here we show that PARP is a positive regulator of the E2 protein of human papillomavirus type 18 (HPV-18). PARP interacted with the COOH terminal region of HPV-18 E2 in vitro. The E2 interaction domain within PARP is located in the NH 2 -terminal zinc finger motif and the BRCT motif included in the automodification domain. Overexpression of either wild type or the NH 2 -terminal region of PARP containing zinc finger and BRCT stimulated E2-dependent transcription. Gel retardation assay indicates that PARP augments DNA binding activity of E2 in vitro. We also show that PARP-1 is recruited to E2-dependent promoter in vivo using ChIP assay. These results suggest that PARP serves a transcriptional co-activator in E2-dependent transcription by interacting directly with the HPV E2 protein.
Introduction
Human papillomaviruses (HPVs) are small doublestranded DNA viruses that target epithelial tissues for infection (zur Hausen, 1996 (zur Hausen, , 2000 . The E2 protein is a transcriptional activator/repressor that regulates viral transcription and DNA replication in vivo (Bouvard et al., 1994; Cripe et al., 1987; Stubenrauch et al., 1998) . Full-length E2 protein can support viral transcription and DNA replication, whereas alternatively spliced forms of the E2 protein that lack the amino-terminal domain act as repressors of transcription (Bouvard et al., 1994; Choe et al., 1989) . In vitro studies showed that low amounts of E2 protein can activate E6 promoter of HPV-18, whereas increasing amounts of E2 result in repression of E6 promoter (Steger and Corbach, 1997) . E2 cooperatively stimulates transcription with several cellular cofactors (Li et al., 1991; Breiding et al., 1997; Lee et al., 2000 Lee et al., , 2002 . For the transactivation function, activation domain or DNA binding domain of E2 protein can act as protein binding sites for viral or cellular proteins (Breiding et al., 1997; Lee et al., 2000; Rank and Lambert, 1995) . In addition, the transactivation function of E2 is essential for the promotion of apoptosis in HeLa cells (Desaintes et al., 1997 (Desaintes et al., , 1999 Webster et al., 2000) . Transcriptional repression by E2 results from the binding of HPV E2 to one of the four E2 binding sites located adjacent to the TATA box of the HPV early promoter (Bernard et al., 1989) . Binding of E2 molecules to these sites prevents the binding of TFIID to the TATA sequence and, thus, reduces early gene expression (Demeret et al., 1994) . This repression by E2 has been postulated to play a role in the down regulation of transcription of the HPV transforming genes E6 and E7. The integration of viral genomes into the cellular genome disrupts E2 expression and leads to an increased expression of E6 and E7 and progression to malignancy (Desaintes et al., 1997) . By repressing E6/E7 expression, E2 is able to induce the suppression of cell growth and p53-independent apoptosis in HPV positive cell lines (Desaintes et al., 1999) . Desaintes et al. (1997 Desaintes et al. ( , 1999 reported that E2 transcriptional activation function is required for URR promoter repression, suggesting that transcriptional activation potential of E2 and its partners may be involved in host growth control.
DNA strand-breaks introduced either directly by ionizing radiation or indirectly following enzymatic incision at a DNA lesion trigger the endogenous synthesis of poly(ADP-ribose) by poly(ADP-ribose) polymerase (PARP) (Hayaishi and Ueda, 1977) . At the vicinity of a break, PARP transfers ADP-ribose moieties from NAD+ to a limited number of nuclear proteins involved in chromatin architecture and/or in DNA metabolism, including DNA polymerase a (Yoshihara et al., 1985) , DNA polymerase b (Ohashi et al., 1986) , topoisomerase I (Ferro and Olivera, 1984) , histones (Huletsky et al., 1985) , p53 (Wesierska-Gadek et al., 1996) , DNA-PK (Ruscetti et al., 1998) and PARP itself (de Murcia and Menissier de Murcia, 1994). Because of the negative charges of a long, branched polymer side chain of ADP-ribose moieties, poly(ADP-ribosylated) proteins lose their affinity for DNA. PARP is composed of 1014 amino acids that specify three discrete functional domains: a Zinc-finger domain acting as an in DNA strand-break sensor (de Murcia and Menissier de Murcia, 1994) , an automodification domain containing a BRCA1-C terminus (BRCT) motif involved in proteinprotein interactions (Bork et al., 1997; Zhang et al., 1998) and a catalytic domain bearing the basal polymerizing activity stimulated by DNA breaks (de Murcia and Menissier de Murcia, 1994; D'Amours et al., 1999) . Recent studies have implicated the role of PARP as a transcriptional co-activator during normal cell cycle. PARP can act as a repressor as well as a coactivator of bound transcription factors, indicating that PARP may modulate transcriptional function of its partners using different biochemical mechanisms (D'Amours et al., 1999) .
PARP-1 has been reported to be involved in many cellular processes, such as DNA damage and repair, DNA replication, differentiation, apoptosis and nuclear hormone signaling (D'Amours et al., 1999) . In this study, we show that PARP also functions as a coactivator of HPV-E2-mediated transcription through the direct interaction with the HPV E2 protein. The NH 2 -terminus of PARP is sufficient for stimulating E2-dependent transcription.
Results

PARP binds to HPV-18 E2 protein
PARP has been shown to inhibit nuclear receptormediated transcription and enhance the ability of BMyb to activate transcription, implying that PARP has a role in transcriptional regulation (Miyamoto et al., 1999; Cerevellera and Sala, 2000) . HPV E2 protein plays a central role in the regulation of the viral transcription and DNA replication (McBride et al., 1991) . Therefore, it is possible that post-translational modification of chromatin by poly(ADP-ribosyl)ation as well as acetylation (Lee et al., 2000) contributes to the regulation of transcription. We thus determined whether PARP could interact with HPV E2 and modulate E2-dependent transcriptional regulation.
To determine whether HPV-18 E2 and PARP associated in vivo, we transiently transfected 293T cells with plasmids that expressed GST-tagged HPV-18 E2 and HA-tagged PARP. The association of HA-PARP with GST-E2 was detected by Western blotting using anti-HA monoclonal antibody (Figure 1a) . We performed the same experiments to find whether the endogenous PARP also bound to E2 in vivo. As shown in Figure 1b , the endogenous PARP bound to E2 in vivo. The existence of E2-PARP complex was further confirmed by the intracellular localization of PARP and HPV E2 using confocal microscopy ( Figure 1c ). Co-transfection of PARP brought GFP-E2 into nuclear dots, indicating that PARP and HPV-18 E2 proteins are co-localized in nucleus.
To decipher the PARP binding site within E2, we purified various deletion forms of GST-E2 fusion proteins and in vitro binding assays were performed (Figure 2a) . In vitro-translated PARP bound specifically to GST-E2 (Figure 2a , left column), GST-18E2C (aa 261 -365 of the HPV-18 E2 protein), while PARP did not interact with GST alone or GST-18E2N (aa 1 -261 of the HPV-18 E2 protein (Figure 2a , right column). From these results, we conclude that the COOH-terminus of the HPV-18 E2 protein interacts with PARP. We performed GST pulldown assays using in vitro-translated deletion mutants PARP and GST-E2C (Figure 2b ). First, we showed that full-length PARP bound to GST-E2C in vitro. Next, we performed GST pulldown assay using various fragments of PARP and GST-E2C. E2 bound to the NH 2 -terminus (aa 1 -523) of PARP-1 (6.4%), while E2 did not interact with the catalytic domain of PARP-1 and luciferase in vitro. It suggests that E2 binds to the NH 2 -terminus and the BRCT domain of PARP, but not to the catalytic domain of PARP in vitro. To show whether E2 interacts with PARP directly, we carried out in vitro binding assay using recombinant PARP and GST-E2 protein. As shown in Figure 2c , PARP bound to E2 directly. As a control, we used GST and GST-E2N and they did not bind to PARP in vitro.
PARP activates specifically E2-dependent transcription
The identification of a specific interaction between E2 and PARP may suggest that PARP might play a role in HPV E2-dependent transcription. To determine the physiological relevance of this protein -protein interaction, we constructed expression plasmids that contained various PARP deletion or missense mutants and tested whether the mutants could modulate E2-dependent transcription. Because PARP consists of distinct regulatory and catalytic domains, it is wellknown that overexpression of a full-length version of the enzyme carrying a mutation in the catalytic site (D993A) or a truncated version that codes specifically for a regulatory and not a catalytic function can inhibit poly(ADP-ribosyl)ation effectively in a trans-dominant manner (Molinete et al., 1993) . A schematic diagram of the domain structure of PARP and its mutant forms are shown in Figure 3a . The luciferase reporter plasmid (p2626E2BS-Luc), containing synthetic tandem repeats of the E2 DNA binding site 5' upstream of luciferase gene, was co-transfected with the plasmids encoding E2 and the wild type or mutant form of PARP into C33A cells. Wild type PARP activated E2-dependent transcription as did the COOH-terminal deletion mutant, PARP-1 (68 kDa). Catalytically inactive PARP-1(D993A) mutant also stimulated E2-dependent transcription (Figure 3b ). The catalytic domain mutant of PARP-1 (54 kDa) did not augment E2-dependent transcription. We checked the relative expression levels of E2 to confirm that PARP and PARP derivatives did not modulate E2 expression level in vivo. Each PARP proteins were expressed similarly in the transfected cells (Figure 3b , Bottom). These results suggest that the NH 2 -terminus of PARP including the DNA binding domain and BRCT domain, stimulates HPV E2-dependent transcription and the catalytic activity of PARP is not necessary for augmentation of E2-dependent transcription by PARP.
The COOH-terminal DNA binding domain of E2 protein is required for efficient transactivation of E2-dependent transcription by PARP To elucidate the domain of HPV-18 E2 protein required for co-activation of E2-dependent transcription by PARP, we engineered expression plasmids that encoded the GAL4 DNA binding domain fused to either full-length E2 (pM-E2) or a truncated version of HPV-18 E2 that contained the NH 2 -terminal transcriptional activation domain (pM-E2AD) for the transient transfection experiments (Figure 4a ). pFR-Luc, which contains the GAL4 dependent promoter fused to the luciferase reporter gene, was co-transfected with pM-E2 into C33A cells in the absence or presence of an expression plasmid encoding either PARP or the PARP NH 2 -terminal region. Both the full-length PARP-1 and PARP-1 (68 kDa) up-regulated GAL4-E2-dependent (Figure 4b ). Next, we performed similar transient transfection assays with HPV-18 E2 that contained the NH 2 -terminal transcriptional activation domain (pM-E2AD) (Figure 4c ). This truncated form of the GAL4-E2 fusion protein activated the pFR-Luc promoter efficiently (15-fold), but did not respond to PARP. pM alone also activated GAL4-dependent transcription only about twofold, and did not respond to PARP (Figure 4d ). These results indicate that the COOH-terminal region of E2, which contains the DNA binding domain, not the NH 2 -terminal transcriptional activation domain, is required for the stimulatory role of PARP on E2-dependent transcription.
PARP enhances DNA binding of E2 in vitro
Since PARP activates transcriptional activation of E2, we cannot rule out a possibility that PARP affects DNA binding ability of E2 and thereby modulates transcriptional activation of E2. Therefore, we examined the effect of PARP in gel retardation using GST-E2. As shown in Figure 5a , when labeled probe containing E2BS was incubated with GST-E2, two major shifted bands were observed ( Figure 5a , lane 2, C2 and C4). Addition of 10-fold excess of the oligonucleotide containing E2BS sequence (Figure 5a , Figure 2 In vitro binding between E2 and PARP (a) Direct interaction of GST-E2C with the PARP protein in vitro. In vitro-translated and 35 S-labeled full-length PARP products were incubated with GST alone or with GST-E2, GST-E2N, or GST-E2C immobilized on glutathione beads. Labeled proteins (arrows) that are retained on the beads after extensive washing were analysed by SDS -PAGE and autoradiography, along with 10% of the translated products used in each incubation (Input). Recombinant GST fusion protein used in GST pulldown assay was shown in bottom. (b) Top, Schematic representation of PARP proteins used in GST pulldown assay. Bottom, Detailed mapping of PARP. In vitro-translated,
35
S-labeled PARP deletion mutants and luciferase were incubated with GST-E2C immobilized on glutathione beads. Proteins that remained on the beads after extensive washing were analysed by SDS -PAGE and autoradiography. The percentages of PARP bound to GST-E2C (Binding (%)) were shown in bottom of each lane. Recombinant GST fusion protein used in GST pulldown assay was shown in right panel. (c) Direct interaction between E2 and PARP in vitro. Recombinant PARP was incubated with purified GST, GST-E2, and GST-E2N and immobilized on GST resin. Bound proteins were separated on a SDS -PAGE and analysed by Western blot using anti-PARP antibody (Figure 5a, lane 4) . did not affect the gel mobility shift. These results showed the specificity of DNA-protein complex. When recombinant PARP was added in the presence of E2, dramatic change and increase of DNA binding of E2 was observed and novel shifted bands were shown while any change was not observed by adding recombinant PARP protein in the absence of E2. Addition of PARP or E2 antibody resulted in supershift complexes (Figure 5a, lanes 9 and 11) .
Addition of control antibody (anti-HA) have no effect on mobility of E2-DNA complex (Figure 5a, lane 10) . We also performed gel shift assay using nuclear extracts (Figure 5b ). Addition of E2 or PARP antibody resulted in supershift complex (Figure 5b, lanes 3, 4) . No variation in complexes formation was observed with control antibody (Figure 5b , lane 5). Previous reports indicated that PARP increases the on rate of proteins binding to DNA in nuclear extract or reconstitute experiments (Nie et al., 1998; Plaza et al., 1999) . These results indicate that PARP enhances DNA binding of E2 and this ability may be contributed to E2-dependent transcriptional activation. Figure 5 Gel retardation assay of E2. (a) Indicated components (top) were included in each binding reaction and GST-E2-DNA complex (C0, C1, C2, C3 and C4). Ten-fold molar excess of unlabeled oligonucleotides containing CRE binding site was used in the competition reactions. Lane 1, probe alone, lanes 2 -4, probe plus GST-E2 (100 ng) (lane 3, with 10-fold cold E2BS probe; lane 4, with 10-fold cold CRE probe); lanes 5 -6, probe plus GST-E2 plus PARP (100, 500 ng); lanes 7 -8, probe plus PARP (100, 500 ng); lanes 9 -11, probe plus GST-E2 plus PARP (100 ng) plus indicated antibodies. The retarded complex was indicated by arrow. (b) Nuclear extracts of 293T cells (1 mg) were incubated with antibody for 30 min at 308C. Nuclear extracts were made by 293T cells transfected with GST-E2 and PARP-1 expression vector. Lane 1, probe alone, lane 2, probe plus nuclear extract; lanes 3 -5, probe plus nuclear extract plus indicated antibodies (3 ml)
HPV-18 E2 recruits PARP-1 to the E2 binding site in vivo
We next asked whether HPV-18 E2 protein targets PARP-1 to the cognate promoter in vivo. In order to test the association of PARP-1 with 2626E2BS promoter, we performed a ChIP analysis on 293T cells which are transfected with the E2 dependent promoter in combination with pCG-18E2 or a control vector. The presence of the specific promoter in the chromatin immunoprecipitates was detected by semiquantitative PCR using specific pairs of primers that span the p2626E2BS-Luc sequence region. Antibodies to HA-PARP-1 and E2 clearly precipitated the reporter sequence while no antibody failed to precipitate significant reporter DNA (Figure 6 ). The ChIP assay shows that PARP-1 is bound to promoter region via E2 in vivo.
Discussion
In this study, we have shown that PARP physically associates with the HPV-18 E2 protein and activates E2-dependent transcription. We also demonstrated that the NH 2 -terminal domain of PARP is the sole requirement for transcriptional co-activation of E2 by PARP. The identification of PARP as a potential coactivator of E2-dependent transcription is an important extension of the cellular functions of PARP, raising questions regarding the role of PARP in viral transcription. Furthermore, E2 from other strains of HPV also bind to PARP in vitro, suggesting that PARP is a general co-activator of the HPV E2 protein (data not shown).
There is increasing evidence that PARP has a transcriptional co-activator activity during normal cell cycle (Cervellera and Sala, 2000; Meisterernst et al., 1997; Butler and Ordahl, 1999; Kannan et al., 1999; Oliver et al., 1999; Plaza et al., 1999) . Previous works showed that the co-activator function of PARP is inhibited by automodification of the enzyme, and is mediated by the DNA binding domain of PARP. However, the stimulatory effect of PARP in transcription was independent of DNA damage, indicating that PARP may behave as a co-activator of transcription during the normal cell cycle. Recently, it was documented that PARP interacts with B-Myb and that the catalytic activity of PARP is not required to enhance B-Myb transcriptional activation function (Cervellera and Sala, 2000) . We hypothesize that other cellular transcriptional activators may interact with PARP to enhance the transcription of specific target genes.
The NH 2 -terminus of PARP contains two zinc finger domains and two helix-turn-helix motifs (D'Amours et al., 1999; Dantzer et al., 2000) . This domain recognises nicked DNA and has a crucial role in DNA damage detection and signaling. Nuclear receptor RXRa interacts with this zinc finger domain of PARP (Miyamoto et al., 1999) . Thus, this domain of PARP acts also as a protein -protein interaction interface (D'Amours et al., 1996) . By binding with host or viral factors, PARP may modulate their function by an enzymatic activity-dependent or independent manner. In the enzymatic activity-dependent mechanism, PARP transfers ADP-ribose polymers to target factors and down-regulates their function: this is the case for target factors such as RXRa and p53 (Wesierska-Gadek et al., 1996; Miyamoto et al., 1999) . In contrast, PARP can enhance the biological activity of target factors such as B-myb (Cervellera and Sala, 2000) and HPV E2 in an enzymatic activity-independent manner. An increasing number of transcription factors or transcription coactivators have been reported to be associated with PARP, including AP-2 (Kannan et al., 1999) , Oct-1 (Nie et al., 1998) , YY1 (Oei et al., 1997) and TEF-1 (Butler and Ordahl, 1999) . Elucidation of the precise roles of PARP in transcriptional activation with and without enzymatic activity requires further investigation. One possible mechanism is that PARP may stabilize complex formation between E2 and other coactivators such as CBP through complicated proteinprotein interaction (Anderson et al., 2000) .
Transcriptional studies showed that PARP activates E2-dependent transcription and the catalytic activity of PARP is not required for E2-dependent transcription. Interestingly, the transactivation domain of E2, which binds to CBP/p300 (Lee et al., 2000) , is not required for the interaction with PARP. Since PARP is known to be one active component of PC1 and NH 2 -terminal region of PARP is sufficient for transcriptional activation in vitro (Meisterernst et al., 1997) , we Figure 6 HPV E2 recruits PARP-1 into p2626E2BS-Luc promoter region in vivo. p2626E2BS-Luc or pGL2-Basic was cotransfected into 293T cells with or without pCG-18E2. Cells were crosslinked and immunoprecipitated with or without antibodies to anti-HA, anti-E2 as described in Materials and methods. Precipitated DNA was then PCR amplified with primers to the reporter plasmids around the p2626E2BS-Luc or pGL2-Basic and resolved on an agarose gel speculate that PARP may serve as a bridging factor between co-activators and specific transcription factor E2. In addition, out gel retardation assay data clearly indicate that PARP increase DNA binding activity of E2. By doing so, we think that PARP may stabilize E2-DNA complex formation and may augment E2-dependent transcription.
The biological meaning of E2-PARP interaction is unclear. However, we note that E2-PARP association is also likely to link another function of E2 unrelated to viral gene expression. PARP is known to be important for genomic stability and the up-regulation of E2F-1 promoter (Wang et al., 1997; SimbulanRosenthal et al., 1999) . In addition, PARP can affect the telomere length control (d'Adda di Fagagna et al., 1999) . These data indicate that PARP may be a cofactor for maintaining viral genome and E2-mediated senescence since transcriptional potential of E2 is important for papillomavirus DNA replication and replicative senescence. Further studies for the regulation of host gene expression by E2 is required for understanding E2-mediated replicative senescence. It is known that PARP-1 is able to modulate cell differentiation and tumorigenesis (Ohashi et al., 1984; Masutani et al., 2001; Smulson et al., 1995) . HPV oncoproteins can modulate the ability of primary human keratinocytes to differentiate (Funk et al., 1997; Jones et al., 1999; Sherman and Schlegel, 1996; Sherman et al., 1997) . By repressing E6/E7 expression, E2 is able to induce the suppression of cell growth (Desaintes et al., 1999) and may relieve E6/E7-mediated suppression of keratinocyte differentiation. It is reported that E2 transcriptional activation function is required for URR promoter repression, suggesting that protein -protein interaction between PARP-1 and E2 is contributed to switch from latency to productive replication. Alternatively, co-activator function of PARP-1 may be important for DNA damage signaling. E2 and PARP-1 may activate the E6/E7 promoter. As a consequence, HPV oncoproteins may overcome cell death signaling in order to protect viral genome and to maintain viral life cycle.
In conclusion, our data indicate that PARP is participated in E2-driven transcriptional activation in a catalytic activity independent manner. This finding helps to understand the molecular connections between E2 and cellular factors.
Materials and methods
Plasmids pCG-18E2 was kindly provided by Dr F Thierry. pEBG-18E2 was previously described (Lee et al., 2000) . HA-tagged PARP expression vectors (full length PARP-1, BRCT and 54 kDa) were made by inserting PARP cDNAs into pSRa1 vector or pCDNA3 vector using appropriate primers. We inserted SV40 nuclear localized signal into the NH 2 terminus of BRCT and 54 kDa expression plasmids. pM-18E2 (aa 1 -365, full size) and pM-18E2AD (aa 1 -261 of HPV-18E2, the activation domain) were synthesized using PCR and the appropriate primers. Serial deletion mutants of PARP were made by PCR method using appropriate primers. p2626E2BS-Luc was provided by Dr R Kovelman. The pFR-Luc and pM plasmids were purchased from Clontech (CA, USA).
Cells, transfection and reporter assay
Human embryonic kidney cell 293T and human cervical cancer cell C33A cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Twenty-four hours before transfection, 3610 5 cells were plated in 60 mm plates. Transfections were performed either by the standard calcium phosphate method (Graham et al., 1977) or by using lipofectamine (Gibco -BRL). The transfected plasmids were prepared by the Qiagen procedure (Qiagen, Hilden, Germany), and the total amount of DNA transfected was adjusted with pcDNA3 or blank plasmid DNA. Equal amounts of cell lysates were employed for the detection of luciferase activity. Luciferase activity was measured by luciferase assay kit (Promega) using luminometer and each assay is normalized by b-galactosidase activity.
Glutathione S-transferase (GST) pulldown assays
Radiolabeled, in vitro-translated proteins were incubated with GST fusion protein in T buffer (50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, 0.7 mg/ ml bovine serum albumin, 0.5% Nonidet NP-40). After incubation at room temperature for 20 min, glutathionesepharose beads were added, and this mixture was incubated on a rotating machine (Nutator) for 1 h at room temperature. The beads were washed four times with T buffer, 56loading dye (60 mM Tris-HCl (pH 6.8), 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, 0.5% bromophenol blue) was added, and the proteins were subjected to Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS -PAGE).
In vitro binding assay GST-E2 was purified using expression of pEBG-18E2 in 293T cells. PARP was purchased from BIOMOL Research Laboratories, Inc. GST fusion protein (about 5 mg) and recombinant PARP was incubated with Glutathione Sepharose 4B (Amersham Pharmacia Biotech) at 48C for 3 h. The beads were washed three times in EBC, and then resuspended in a sodium dodecyl sulphate (SDS) gel loading buffer. The eluted proteins were separated by 10% SDS polyacrylamide gel electrophoresis (PAGE), transferred to nitrocellulose membrane, and then immunoblotted and detected by ECLTM (Amersham Pharmacia Biotech).
Mutagenesis
PARP mutants (D993A and 68 kDa) were made using the QuickChange site-directed mutagenesis Stratagene kit (Stratagene, San Diego, CA, USA), according to the manufacturer's instructions.
Immunoprecipitation
Cells expressing GST and GST-18E2 with or without HA-PARP were lysated in EBC buffer (Lee et al., 2000) and incubated with 25 ml of a 1 : 1 suspension of glutathioneSepharose in EBC buffer for 4 h at 48C with rocking. The Glutathione-bound complexes were then washed three times with EBC buffer and boiled at 958C for 5 min in SDS sample buffer. Immunoblot analysis was carried out using anti-HA antibody (12CA5, Boehringer Mannheim) or anti-GST monoclonal antibody.
Immunofluorescence
293T cells in six well plates were transfected in combination with (2 mg DNA per well) 1 mg of GFP-E2 and HA-PARP. Cells were fixed and immunostained *24 h after transfection. HA antibody was detected using 12CA5 and rhodamineconjugated secondary antibody.
Gel retardation assay
293T cell nuclear extracts were prepared as described (Pugh, 1995) . Synthetic oligonucleotides containing two E2BS (5'-CTAGG ACCGAAAACGG TTCA ACCGAAAACGGTTG-3') were labeled with g-32 P-ATP by T4 polynucleotide kinase and annealed with complementary strand. Labeled probe (*100 fmol) was incubated with 12.5 ng of bacterially expressed GST or GST-E2 in the absence or presence of PARP in a binding buffer (12 mM HEPES (pH 7.9), 60 mM KCl, 0.5 mM EDTA, 5 mM MgCl 2 , 4 mM Spermidine, 500 ng BSA, 0.1% NP-40, 10% glycerol, 5 mg of salmon sperm DNA and 1 mg of poly (dI×dC) at 308C for 30 min. The reaction was terminated by loading on a 5% native polyacrylamide gel containing 0.56TBE (45 mM Tris base, 45 mM boric acid, 1 mM EDTA (pH 8.0)). After electrophoresis in 0.56TBE, the gel was dried and subjected to autoradiography. For the confirmation of specificity of DNA-protein complex, 10-fold excessive unlabeled competitor oligonucleotides containing CRE (Promega) were used.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed essentially as described in the Upstate Biotechnology protocol. Briefly, a 10 cm dish of 50% confluent 293T cells was transfected with 2 mg of p2626E2BS-Luc reporter plasmid and/or 2 mg of pCG-18E2 plasmid. After 24 h cells were cross-linked and treated as per the protocol. About 1 mg of each indicated antibody was used (Anti-hemagglutinin (HA) from Roche; Anti-E2 was obtained from Dr Michael R Botchan). Precipitated DNA was resuspended in 50 ml of water. To detect the precipitated plasmid sequence, 1 -5 ml of DNA was used in a 100 ml, 22 -30 cycles PCR with primers (for p2626E2BS-Luc, Luc5 (5'-ATGGAAGACGCCAAAAACAT-3'), Luc3 (5'-CATAGCTTCTGCCAACCGAA-3').
